Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and chemo-free regimens, have transformed the therapeutic landscape. This expert opinion article, based on insights from 14 experts worldwide, explores the evolving role of autologous stem cell transplantation (ASCT) in MCL management, and the treatment approaches for ASCT-ineligible patients. It discusses the benefits and limitations of emerging therapies, emphasizing personalized treatment approaches to optimize clinical outcomes. Tailoring strategies to individual patient profiles, considering genetic markers, comorbidities, and regional healthcare resources, is crucial. The evolving MCL landscape prioritizes personalized care, with BTKi emerging as an effective first-line option for ineligible ASCT patients and a robust alternative to ASCT. Global collaboration and knowledge sharing are essential to advance MCL treatment and ensure optimal care.